Roche and Plexxikon entered into agreement to develop and commercialize Plexxikon’s PLX4032, targeted cancer therapy. The deal could be worth up to US$706 M to Plexxikon if specific milestones and sales targets are met.
Roche also entered into collaborative alliance with InterMune to develop and commercialize InterMune’s drug candidates from HCV protease inhibitor including ITMN-101, which is in preclinical development for treating hepatitis C. The deal could be worth up to US$530 M to InterMune.